EU launch for Medtronic's Nanostim:
This article was originally published in Clinica
Medtronic has launched Nanostim, its synthetic bone paste for use in surgical procedures, in the EU and other non-US markets. The nanohydroxyapatite-based bone graft substitute provides a supporting structure to aid bone healing in places where gaps exist in the bone. The paste can be filled into defects regardless of their shape, and because it consists of nanocrystals, does not harden after application, claimed Medtronic's Memphis, Tennessee-based spinal and biologics division.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.